Algae-Based Biopharmaceuticals
This book constitutes a key reference on the use of algae in the BFs production field; providing an updated outlook on the achievements accomplished thus far and transmitting a prospective view for this biotechnological application.This book provides a de
- PDF / 5,407,832 Bytes
- 172 Pages / 439.43 x 683.15 pts Page_size
- 38 Downloads / 234 Views
Algae-Based Biopharmaceuticals
Algae-Based Biopharmaceuticals
Sergio Rosales-Mendoza
Algae-Based Biopharmaceuticals
Sergio Rosales-Mendoza Universidad Autónoma de San Luis Potosí San Luis Potosí Mexico
ISBN 978-3-319-32230-8 ISBN 978-3-319-32232-2 DOI 10.1007/978-3-319-32232-2
(eBook)
Library of Congress Control Number: 2016941538 © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Cover illustration: Laurent Dambies / Fotolia Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG Switzerland
Preface
Photosynthetic microorganisms have been used for the benefit of human beings since ancient times. For instance, the first known report on the use of cyanobacteria as food was published in 1520 by Hernán Cortés, commenting the fact that Aztecs ate tecuitlatl, a cake made from Spirulina that was an important part in their diet. In the case of eukaryotic algae, important biotechnology applications have been developed for many species. The invention of molecular cloning and genetic engineering tools allowed for the development of numerous products that tremendously favored the human and animal health worldwide. For instance, the recombinant biopharmaceuticals (BFs) such as insulin, cytokines, monoclonal antibodies, and subunit vaccines allowed for the treatment, cure, or prevention of many diseases saving millions of lives. Improvements on the platforms for producing these recombinant BFs are under development or still needed. During the last decade, algae species have been explored as a next-generation platform for BFs production with clear advantages in terms of efficacy, safety, and cost. The current developments comprise the production of several BFs in some algae species, which have been evaluated at the preclinical level with positive outcomes. Moreover, the ambitious objectives in this field consist in the use of whole algae ce
Data Loading...
